Lexaria Bioscience Corp. Provides Strategic Update
Lexaria Bioscience (NASDAQ:LEXX) announced strategic updates including engagement of a global life‑science business development advisory firm, completion of an equity financing raising $4.0 million gross, and award of 4 new patents covering diabetes, epilepsy, antiviral delivery and infused food/beverage applications (grant dates Jul–Oct 2025).
The funding extends operations beyond 2025, supports expanded R&D into 2026, and enables increased outreach to pharmaceutical and biotech partners. Final results from a Phase 1b Australian GLP‑1 study are anticipated and further R&D budget decisions will be announced later.
Lexaria Bioscience (NASDAQ:LEXX) ha annunciato aggiornamenti strategici tra cui l'ingaggio di una società globale di sviluppo business nel settore life-science, il completamento di un finanziamento azionario che ha raccolto 4.0 milioni di dollari lordi e l'assegnazione di 4 nuove domande di brevetto che coprono diabete, epilessia, erogazione antivirale e applicazioni alimentari/bevande infuse (date di concessione Jul–Oct 2025).
Il finanziamento estende le operazioni oltre il 2025, sostiene l'espansione della R&S nel 2026 e consente una maggiore disseminazione verso partner nel settore farmaceutico e biotecnologico. I risultati finali di uno studio australiano GLP-1 di fase 1b sono attesi e ulteriori decisioni sul budget R&S saranno annunciate in seguito.
Lexaria Bioscience (NASDAQ:LEXX) anunció actualizaciones estratégicas que incluyen la contratación de una firma global de desarrollo de negocio en ciencias de la vida, la finalización de una financiación de capital que recaudó $4.0 millones brutos y la adjudicación de 4 patentes nuevas que cubren diabetes, epilepsia, entrega antiviral y aplicaciones de alimentos/bebidas infusionados (fechas de concesión jul–oct 2025).
El financiamiento extiende las operaciones más allá de 2025, respalda una expansión de I+D en 2026 y permite un mayor alcance hacia socios farmacéuticos y biotecnológicos. Se esperan los resultados finales de un estudio australiano GLP-1 de Fase 1b y se anunciarán más decisiones de presupuesto de I+D más adelante.
Lexaria Bioscience (NASDAQ:LEXX)은 글로벌 생명과학 비즈니스 개발 자문회사와의 협력, 4.0백만 달러 총수입 자본금 조달 완료, 당뇨병, 간질, 항바이럴 전달 및 주입형 식품/음료 응용 분야를 다루는 새로운 4건의 특허 부여를 포함한 전략 업데이트를 발표했습니다(허가일: 2025년 7월–10월).
자금 조달은 2025년 이후의 운영을 연장하고 2026년으로의 연구개발 확장을 지원하며 제약 및 생명공학 파트너에 대한 협력을 확대합니다. GLP-1에 관한 호주 1b상 최종 결과가 기대되며 추후 R&D 예산 결정이 발표될 예정입니다.
Lexaria Bioscience (NASDAQ:LEXX) a annoncé des mises à jour stratégiques incluant l'engagement d'une firme mondiale de développement commercial dans le domaine des sciences de la vie, l'achèvement d'un financement par actions ayant levé 4,0 millions de dollars brut et l'attribution de 4 nouveaux brevets couvrant le diabète, l'épilepsie, la délivrance antivirale et les applications alimentaires/buvables infusées (dates de concession juil.–oct. 2025).
Le financement prolonge les opérations au-delà de 2025, soutient l'expansion R&D en 2026 et permet d'accroître les échanges avec des partenaires pharmaceutiques et biotechnologiques. Les résultats finaux d'une étude GLP-1 australienne de phase 1b sont attendus et d'autres décisions liées au budget R&D seront annoncées plus tard.
Lexaria Bioscience (NASDAQ:LEXX) kündigte strategische Updates an, darunter die Beauftragung einer globalen Life-Science-Business-Development-Beratungsfirma, der Abschluss einer Eigenkapitalfinanzierung in Höhe von 4,0 Millionen US-Dollar brutogewinn und die Vergabe von 4 neuen Patenten zu Diabetes, Epilepsie, antiviraler Wirkstofffreigabe und Infusion Food/Getränke-Anwendungen (Vergabedaten Jul–Okt 2025).
Die Finanzierung verlängert die operativen Aktivitäten über 2025 hinaus, unterstützt eine erweiterte F&E in 2026 und ermöglicht eine größere Ansprache von pharmazeutischen und biotechnologischen Partnern. Endergebnisse einer australischen GLP-1-Studie der Phase 1b werden erwartet, und weitere F&E-Budgetentscheidungen werden später bekannt gegeben.
أعلنت Lexaria Bioscience (ناسداك: LEXX) عن تحديثات استراتيجية بما في ذلك تعيين شركة استشارية عالمية في تطوير الأعمال في علوم الحياة، وإتمام تمويل أسهم بجمع 4.0 مليون دولار إجمالاً، ومنح 4 براءات اختراع جديدة تغطي السكري، والصرع، وتوصيل مضاد للفيروسات وتطبيقات الأطعمة/المشروبات المحقونة (تواريخ المنح Jul–Oct 2025).
يمد التمويل العمليات إلى ما بعد 2025، ويدعم توسيع البحث والتطوير إلى 2026، ويسمح بتوسيع التواصل مع شركاء في صناعة الأدوية والتكنولوجيا الحيوية. من المتوقع نتائج نهائية من دراسة GLP-1 الأسترالية في المرحلة 1b وسيتم إعلان قرارات ميزانية البحث والتطوير لاحقاً.
Lexaria Bioscience (NASDAQ:LEXX) 宣布战略更新，其中包括聘请一家全球生命科学商业发展咨询公司，完成一轮股权融资，毛额募集400万美元，并授予4项新专利，覆盖糖尿病、癫痫、抗病毒递送以及注入型食品/饮料应用（授权日期为2025年7–10月）。
这一资金将运营期延长至2025年以后，支持2026年的研发扩展，并使与药品和生物技术伙伴的合作更为广泛。预计澳大利亚GLP-1阶段1b研究的最终结果，并将稍后宣布更多研发预算决策。
- Gross equity financing of $4.0 million completed
- Awarded 4 patents with grant dates Jul–Oct 2025
- Hired global life‑science business development advisory firm
- Existing operations funded through end of 2025
- No partnering counterparties disclosed due to confidentiality
- R&D lead times may delay material programs into mid‑2026
- Collaborations may yield limited short‑term economic benefits
Insights
Lexaria gained modest near-term optionality via a
Lexaria’s engagement of a global life science advisory firm and newly available
Risks include the early-stage nature of pharmaceutical applications and that collaborations often cover narrow, limited-value studies. The company also awaits final results from its Phase 1b Australian GLP-1 study, which it expects to report; that readout represents a concrete near-term milestone. Watch patent confirmations (AU 2024202475, US 12,397,042, EP 3858364, AU 2023200736) and the Phase 1b results over the next quarters for evidence that R&D efforts translate into partner interest or licensing activity.
Strategic Business Development Advisory Firm Engaged To Support New Business Development Activities
Lexaria Awarded 4 New Patents
KELOWNA, BC / ACCESS Newswire / October 9, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide the following strategic business update.
For several years, Lexaria has been validating the applicability of its patented DehydraTECH technology across a number of sectors within the pharmaceutical industry. In parallel, Lexaria has pursued as many business opportunities as possible using historically limited internal resources, while acknowledging the early stages of DehydraTECH development for pharmaceutical applications. Lexaria's R&D validation programs have already identified several pharmaceutical areas of interest including, but not limited to: treatments for diabetes control and weight loss, hypertension, seizure disorders, anti-viral applications and hormone replacement.
Lexaria is pleased to announce it has now augmented its ongoing internally led business development activities by hiring a global life science business development advisory firm to help identify and pursue additional collaborative business opportunities around the world. Under the terms of that engagement, new outreach activities to the pharmaceutical and biotechnology sectors are underway. Due to the sensitive strategic nature of licensing and partnering discussions, details of the parties involved will remain confidential.
The resources permitting this expansion of strategic outreach, and key supportive R&D related thereto, have been made available through Lexaria's recently completed equity financing which yielded gross proceeds of
Most R&D projects require several months' lead time for activities including study design, regulatory approvals, and entry into binding contracts with third-party vendors. With this in mind, had the Company not obtained these new funds, the first half of 2026 would have been devoid of vital new R&D programs and their attendant potential for corporate business development. Corporate finance decisions are thus an integral part of the Company's broader strategic goals.
R&D programs evolve hand-in-hand with building and strengthening business and strategic connections in the pharmaceutical and biotechnology industries. Even when successful collaboration agreements are reached, they are often limited in scope to narrowly defined areas of study and the short-term economic benefits to Lexaria might also be limited to those areas of mutual interest. However, because of its broad platform nature, Lexaria's DehydraTECH technology has evidenced advantages and improvements in many different sectors and management believes the Company is now ready for the expanded outreach made possible through the engagement of the noted global life science business development firm.
Empowered with new financial resources, Lexaria is now able to advance its business development and R&D programs through the winter and into the first half of calendar 2026. Once final decisions have been made and budgets have been established, the Company will provide additional updates on its exciting strategic R&D plans.
During this period, we also anticipate the final results from the Company's important Phase 1b Australian study in the GLP-1 sector, expected to evidence patient safety and efficacy with DehydraTECH processing of certain industry-leading GLP-1 and complementary drugs marketed today.
In addition, Lexaria is pleased to announce that it has been awarded 4 new patents, continuing to build upon our already significant intellectual property portfolio. These patents support the immense value of our strategic R&D programs as they cover broad therapeutic applications within the fields of diabetes, hypertension, seizure disorders, antiviral treatments, and more.
The new patents are summarized as follows:
Issued | Patent Certificate Grant Date | Patent |
AU 2024202475 | July 24, 2025 | #24 Compositions and Methods for Treating Epilepsy |
US 12,397,042 | August 26, 2025 | #27 Compositions and Methods for Treating Diabetes |
EP 3858364 | September 17, 2025 | #1 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof |
AU 2023200736 | October 2, 2025 | #18 Compositions and Methods for Enhanced Delivery of Antiviral Agents |
In summary, the proceeds from the recent financing provide Lexaria with the opportunity to enhance our corporate business development and strategic R&D programs for 2026, as well as to continue to broaden and strengthen our patent portfolio. Together, these initiatives are being pursued to give Lexaria additional "shots on goal" and opportunities to build shareholder value.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 54 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering, the Company's anticipated 2026 R&D and business development plans, and the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext. 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
FAQ
What did Lexaria (LEXX) announce on October 9, 2025?
How will Lexaria's $4.0M financing affect LEXX's 2026 plans?
Which patents did Lexaria (LEXX) receive in 2025?
When are the Phase 1b GLP‑1 study results expected for LEXX?
What does hiring a global advisory firm mean for Lexaria shareholders?
